摘要
目的:探讨C-erbB-2、P 53、ER和PR蛋白在乳腺癌中的表达及其临床意义。方法:采用免疫组化SP方法,检测54例乳腺癌组织及其癌旁正常乳腺组织中C-erbB-2、P 53、ER和PR蛋白的表达情况。结果:在54例乳腺癌中C-erbB-2、P 53、ER和PR蛋白阳性表达率分别为87.0%(47/54)、83.3%(45/54)、66.7%(36/54)和61.1%(33/54);C-erbB-2和P 53阳性表达率与临床分期、有无淋巴结转移有关(P<0.05);C-erbB-2、P 53、ER和PR阳性表达率与肿瘤大小无关(P>0.05)。C-erbB-2和P 53共同阳性表达与淋巴结转移有关(P<0.01)。结论:联合检测乳腺癌C-erbB-2、P 53、ER和PR基因蛋白对判断预后和指导内分泌治疗有实用价值。
Objective： To study the expression of C-erbB-2, P53, ER and PR and discuss their relationship and clinical significance in breast carcinoma. Methods： The expression of C-erbB-2, P53, ER and PR protein were detected in 54 cases of breast carcinoma with immunohistochemical S-P technique. Results： in 54 cases of breast carcinoma the positive rates of C-erbB-2：87.0%（47/54）, P53：83.3%（45/54）, ER：66.7%（36/54） and PR：61.1%（33/54）, respectively. There existed correlation between the positive expressions of C-erbB-2 and P53 with clinical stages and lymphatic metastasis （P〈0.05）. There was no correlation between the positive expressions of C-erbB-2, P53, ER and PR with the measurements of the tumor （P〉0.05）. Conclusion： Gene expressions of C-erbB-2, P53, ER and PR possess the practical value in determining prognosis and endocrinotherapy.
出处
《华夏医学》
CAS
2006年第1期20-22,共3页
Acta Medicinae Sinica
